Media ReleasesINOVIQ

View All INOVIQ News

INOVIQ - Positive SubB2M IHC Results for Melanoma

-- Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ’s SubB2M probe to aid in diagnosis of malignant melanoma in tissue samples
-- Data from 144 tissue samples in this feasibility study demonstrated that SubB2M IHC detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions
-- INOVIQ's SubB2M technology detects the pan-cancer biomarker Neu5Gc that is found at elevated levels in multiple human cancers
-- SubB2M-based IHC applications represent a new product opportunity for SubB2M as an IHC reagent in the $1.9b IHC market
-- INOVIQ to seek partners to sublicence the further development and commercialisation of SubB2M IHC tissue-based tests

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.